Pro-oxidant activity of zuclopenthixol in vivo: Differential effect of the drug on brain oxidative status of scopolamine-treated rats

Human and Experimental Toxicology

Volumn 23, Issue 9, 2004, Pages 439-445

  Khalifa, Amani E ^a,b  

^a Ain Shams University   (Egypt)

^b Dept of Pharmacology and Toxicology ^*  (Egypt)

Author keywords

Dementia; Oxidative stress; Rat; Scopolamine; Zuclopenthixol

Indexed keywords

GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; NEUROLEPTIC AGENT; SCOPOLAMINE; SUPEROXIDE DISMUTASE; ZUCLOPENTHIXOL ACETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN LEVEL; BRAIN METABOLISM; CONTROLLED STUDY; DEMENTIA; DOSE RESPONSE; ENZYME ACTIVITY; FACTORIAL ANALYSIS; INTERMETHOD COMPARISON; MALE; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RAT; STATISTICAL SIGNIFICANCE;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; CELL DIFFERENTIATION; CLOPENTHIXOL; DRUG COMBINATIONS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALE; MALONDIALDEHYDE; MUSCARINIC ANTAGONISTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; OXIDOREDUCTASES; RATS; RATS, WISTAR; SCOPOLAMINE; SUPEROXIDE DISMUTASE;

ANIMALIA;

EID: 4844225021     PISSN: 09603271     EISSN: None     Source Type: Journal    
DOI: 10.1191/0960327104ht470oa     Document Type: Article

References (48)

1. Reddy RD, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 33-43.
2. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001; 6: 66-73.
3. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2001; 25: 463-93.
4. Yao JK, Reddy RD, van Kammen DP. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001; 15: 287-310.
5. Andreassen OA, Weber C, Jorgensen HA. Coenzyme Q10 does not prevent oral dyskinesias induced by long-term haloperidol treatment of rats. Pharmacol Biochem Behav 1999; 64: 637-642.
6. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996; 19: 1-17.
7. Behl C, Lezoulac'h F, Widmann M, Rupprecht R, Holsboer F. Oxidative stress-resistant cells are protected against haloperidol toxicity. Brain Res 1996; 717: 193-95.
8. Eranti VS, Gangadhar BN, Janakiramaiah N. Haloperidol-induced extrapyramidal reaction: lack of protective effect by vitamin E. Psychopharmacology (Berl) 1998; 140: 418-20.
9. Sagara Y. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem 1998; 71: 1002-12.
10. Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P, Halliwell B. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 1995; 49: 359-65.
11. Dalla Libera A, Scutari G, Boscolo R, Rigobello MP, Bindoli A. Antioxidant properties of clozapine and related neuroleptics. Free Radic Res 1998; 29: 151-57.
12. Hara S, Endo T, Kuriiwa F, Kano S, Iwata N. Anti-oxidant effect of calmodulin antagonists in rat brain homogenate. Res Commun Chem Pathol Pharmacol 1992; 76: 367-70.
13. Kagan VE, Prilipko LL, Savov VM. Formation of inhibitors of lipid peroxidation during oxidative metabolism of hydrophobic xenobiotics catalyzed by mixed function oxidases. Acta Physiol Pharmacol Bulgarica 1984; 10: 46-56.
14. Cruz R, Almaguer Melian W, Bergado Rosado JA. Glutathione in cognitive function and neurodegeneration. Rev Neurol 2003; 36: 877-86.
15. Deary IJ. Individual differences in cognition: British contributions over a century. Br J Psychol 2001; 92: 217-38.
16. Misane I, Ogren SO. Selective 5-HT(1A) antagonists WAY 100635 and NAD-299 attenuate the impairment of passive avoidance caused by scopolamine in the rat. Neuropsychopharmacology 2003; 28: 253-64.
17. Bejar C, Wang R, Weinstock M. Effect of rivastigmine on scopolamine-induced memory impairment in rats. Eur J Pharmacol 1999; 383: 231-40.
18. Mishima K, Tsukikawa H, Miura I, Inada K, Abe K, Matsumoto Y, Egashira N, Iwasaki K, Fujiwara M. Ameliorative effect of NC-1900, a new AVP(4-9) analog, through vasopressin V(1A) receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. Neuropharmacology 2003; 44: 541-52.
19. Rubaj A, Zgodzinski W, Sieklucka-Dziuba M. The influence of adenosine A3 receptor agonist: IB-MECA, on scopolamine- and MK-801-induced memory impairment. Behav Brain Res 2003; 141: 11-17.
20. El-Sherbiny DA, Khalifa AE, Attia AS, Eldenshary ES. Hypericum perforatum extract demonstrates antioxidant properties against elevated rat brain oxidative status induced by amnestic dose of scopolamine. Pharmacol Biochem Behav 2003; 76: 525-33.
21. Ilic TV, Jovanovic M, Jovicic A, Tomovic M. Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct Neurol 1999; 14: 141-47.
22. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 2002; 64: 1037-48.
23. Dringen R, Hirrlinger J. Glutathione pathways in the brain. Biol Chem 2003; 384: 505-16.
24. Maier CM, Chan PH. Role of superoxide dismutases in oxidative damage and neurodegenerative disorders. Neuroscientist 2002; 8: 323-34.
25. Romain JL, Dermain P, Gresle P, Grignon S, Moisan P, Nore D, Pech G, Benyaya J, Perret I. Efficacy of zuclopenthixol acetate on psychotic anxiety evaluated in an open study. Encephale 1996; 22: 280-86.
26. Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118-21.
27. Paget GE, Barnes JM. Interspecies dosage conversion scheme in evaluation of results and quantitative application in different species. In Laurence DR, Bacharach AL eds. Evaluation of drug activities: pharmacometrics, Volume 1. London and New York: Academic Press, 1964: 160-67.
28. Wanibuchi F, Nishida T, Yamashita H, Hidaka K, Koshiya K, Tsukamoto S, Usuda S. Characterization of a novel muscarinic receptor agonist, YM796: comparison with cholinesterase inhibitors in in-vivo pharmacological studies. Eur J Pharmacol 1994; 265: 151-58.
29. Manzaneque JM, Navarro JF. An ethnopharmacological assessment of the effects of zuclopenthixol on agonistic interactions in male mice. Meth Findings Exp Clin Pharmacol 1999; 21: 11-15.
30. Uchiyama M, Mihara M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978; 86: 271-78.
31. Ellman GL. Tissue sulfhydryl group. Arch Biochem Biophys 1959; 74: 214-26.
32. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-69.
33. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autooxidation of Pyrogallol and a convenient assay for Superoxide dismutase. Eur J Biochem 1974; 47: 469-74.
34. Post A, Holsboer F, Behl C. Induction of NF-kappaB activity during haloperidol-induced oxidative toxicity in clonal hippocampal cells: suppression of NF-kappaB and neuroprotection by antioxidants. J Neurosci 1998; 18: 8236-46.
35. Shivakumar BR, Ravindranath V. Oxidative stress induced by administration of the neuroleptic drug haloperidol is attenuated by higher doses of haloperidol. Brain Res 1992; 595: 256-62.
36. Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998; 155: 1207-13.
37. Spina MB, Cohen G. Exposure of striatal [corrected] synaptosomes to L-dopa increases levels of oxidized glutathione. J Pharmacol Exp Ther 1988; 247: 502-507.
38. Dollery C, Boobis AR, Burley D. Zuclopenthixol. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1991: 209-14.
39. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 1970; 11: 303-14.
40. Modi PI, Kashyap A, Nair VD, Ross GM, Fu M, Savelli JE, Marcotte ER, Barlas C, Mishra RK. Modulation of brain catecholamine absorbing proteins by dopaminergic agents. Eur J Pharmacol 1996; 299: 213-20.
41. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D, Sutcliffe JG. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 2003; 8: 983-93.
42. Hashimoto M, Hashimoto T, Kuriyama K. Protective effect of WEB 1881 FU on AF64A (ethylcholine aziridinium ion)-induced impairment of hippocampal cholinergic neurons and learning acquisition. Eur J Pharmacol 1991; 209: 9-14.
43. Gulyaeva NV, Lazareva NA, Libe ML, Mitrokhina OS, Onufriev MV, Stepanichev MY, Chernysevskaya IA, Walsh TJ. Oxidative stress in the brain following intraventricular administration of ethylcholine aziridinium (AF64A). Brain Res 1996; 726: 174-80.
44. Naarala J, Tervo P, Loikkanen J, Savolainen K. Cholinergic-induced production of reactive oxygen species in human neuroblastoma cells. Life Sci 1997; 60: 1905-14.
45. Hiramatsu M, Murasawa H, Mori H, Kameyama T. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist. Br J Pharmacol 1998; 123: 920-26.
46. Kvaltinova Z, Juranek I, Machova J, Stolc S. Effect of oxidative stress on (3H)-N-methylscopolamine binding and production of thiobarbituric acid reactive substances in rat cerebral cortex membranes. Gen Physiol Biophys 1993; 12: 155-61.
47. El-Etri MM, Ennis M, Jiang M, Shipley MT. Pilocarpine-induced convulsions in rats: evidence for muscarinic receptor-mediated activation of locus coeruleus and norepinephrine release in cholinolytic seizure development. Exp Neurol 1993; 121: 24-39.
48. Hrbek J, Rypka M. Effects of single administration of scopolamine, physostigmine and their combination on biogenic amine levels in rat brain. Acta Univ Palacki Olomuc Fac Med 1990; 121: 271-75.